CTOs on the Move

Luminary Micro

www.luminarymicro.com

 
Luminary Micro is a Austin, TX-based company in the Computers and Electronics sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Lambda Electronics Inc

Lambda Electronics Inc is one of the leading companies in the Computers and Electronics sector.

SPECTAL EVOLUTION INC

SPECTAL EVOLUTION INC is a North Andover, MA-based company in the Computers and Electronics sector.

Ultra Clean Technology

Ultra Clean Technology is one of the leading companies in the Computers and Electronics sector.Ultra Clean Holdings, Inc. is a leading developer and supplier of critical systems and subsystems for the semiconductor capital equipment, flat panel, medical, energy and research industries. Ultra Clean offers its customers an integrated outsourced solution for gas delivery systems and other subassemblies, improved design-to-delivery cycle times, component neutral design and manufacturing and component testing capabilities. Ultra Clean`s customers are primarily original equipment manufacturers for the semiconductor capital equipment, flat panel, medical, energy and research industries. Ultra Clean is headquartered in Hayward, California.

Marubun/Arrow

Marubun/Arrow is a Santa Clara, CA-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.